Head-to-head evidence
TR-012001 vs WD-1603
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Parkinson's Disease
Shared mechanism: dopamine precursor · full Parkinson's Disease pipeline
TR-012001
Developed by SNLD, Ltd.
NCT06212089 · Phase 2 · completed
The study randomly assigned 12 participants to TR-012001 or placebo and masked participants, but it was single-blind and very small. Because no results are posted, it cannot establish whether the primary safety comparisons were favorable or statistically significant.
WD-1603
Developed by Hong Kong WD Pharmaceutical Co., Limited
NCT05036473 · Phase 2 · completed
This randomized, double-blind, placebo-controlled Phase 2 trial in early Parkinson's disease enrolled only 40 patients across three dose groups and placebo. All three doses of WD-1603 produced a statistically significant improvement in combined motor and daily-living function scores versus placebo at 27 days, with the largest effect at the highest dose (p=0.0003), but the very small sample size means these results need confirmation in a larger trial.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: TR-012001's landscape · WD-1603's landscape